tbuckley/cabot-search huggingface dataset:
Thin Stage I Primary Cutaneous Malignant Melanoma
Authors: Umberto Veronesi, Natale Cascinelli, Jerzy Adamus, Charles Balch, Dino Bandiera, A. Barchuk, Rosaria Bufalino, Peter Craig, Jaime De Marsillac, J.C. Durand, A.N. van Geel, Hans Holmstrom, John A. Hunter, Ole G. Jorgensen, Bela Kiss, B. Kroon, Jean Lacour, Ferdy Lejeune, Rona MacKie, Zdenek Mechl, G. Mitrov, Alberto Morabito, Henryk Nosek, R. Panizzon, M. Prade, Pierluigi Santi, E. Van Slooten, Radmilo Tomin, Nikolaj Trapeznikov, Tsanko Tsanov, Marshall Urist, K.D. Wozniak
Journal: New England Journal of Medicine (1988)

Although wide surgical excision is the accepted treatment for thin malignant melanomas, there is reason to believe that narrower margins may be adequate. We conducted a randomized prospective study to assess the efficacy of narrow excision (excision with 1-cm margins) for primary melanomas no thicker than 2 mm. Narrow excision was performed in 305 patients, and wide excision (margins of 3 cm or more) was performed in 307 patients. The major prognostic criteria were well balanced in the two groups. The mean thickness of melanomas was 0.99 mm in the narrow-excision group and 1.02 mm in the wide-excision group. The subsequent development of metastatic disease involving regional nodes and distant organs was not different in the two groups (4.6 and 2.3 percent, respectively, in the narrow-excision group, as compared with 6.5 and 2.6 percent in the wide-excision group). Disease-free survival rates and overall survival rates (mean follow-up period, 55 months) were also similar in the two groups. Only three patients had a local recurrence as a first relapse. All had undergone narrow excision, and each had a primary melanoma with a thickness of 1 mm or more. The absence of local recurrence in the group of patients with a primary melanoma thinner than 1 mm and the very low rate of local recurrences indicate that narrow excision is a safe and effective procedure for such patients.
S99 A Prospective Evaluation of Serial Lung Function in a UK Cohort of Patients with Lymphangioleiomyomatosis (LAM)
Authors: V Navaratnam, O Gbolahan, RB Hubbard, SR Johnson
Journal: Thorax (2012)

<h3>Background</h3> LAM is a rare disease of women in which abnormal smooth muscle cells invade and destroy particularly the lungs and lymphatics. We wanted to relate the progression of the disease with presenting clinical features and to determine rate of decline of lung function in patients to improve prognostic predictions and stratify patients for clinical trials. <h3>Methods</h3> Clinical features and pulmonary function test (PFT) data were collected from 125 patients with a definitive diagnosis of LAM by European Respiratory Society Criteria receiving care at the National Centre for LAM. Ethical approval for use of patient data was obtained and patients gave informed consent. 74 of these patients with more than two sets of PFTs formed the prospective cohort. Patients were grouped into degree of lung function impairment based on FEV1 or DLCO at first presentation: unimpaired; PFTs &gt;80% predicted, mild; 61%-80%, moderate; 40%–60%, severe; &lt;40%. <h3>Results</h3> The median follow-up period was 28.5 months (range 3–262). PFTs declined as the disease progressed (figure shows all prospective FEV1 measurements from presentation). Mean changes for FEV1 were –49.68 ml/yr, FVC –44 ml/yr, and DLCO –0.07 mmol/min/kPa/yr. Rate of change in FEV1 varied between patients with different degrees of lung function impairment at first presentation with change in FEV1 within the groups being: unimpaired –84 ml/yr, mild –32 ml/yr, moderate –59 ml/yr and severe –24 ml/yr. <h3>Conclusion</h3> The rate of decline of FEV1 in this cohort was slower than in previous retrospective studies of patients with LAM. Change in FEV1 varied with degree of lung function impairment being more rapid in those with early disease ie. well preserved lung function at diagnosis. Clinical features at onset may be associated with rate of progression of LAM. These data may be helpful in advising patients on prognosis and designing clinical trials.
Case 26-1994
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Powel H. Kazanjian, Anthony R. Mattia
Journal: New England Journal of Medicine (1994)

Presentation of CaseA 20-year-old woman was admitted to the hospital because of a soft-tissue mass in her forearm.The patient had been well until six months earlier, when she observed the development “overnight” of a firm mass in the left forearm, without antecedent trauma. The mass waxed and waned in appearance but did not become larger and was never erythematous or warm. During the month before entry the mass became tender, and the patient experienced intermittent episodes of numbness in the left wrist and palm. She came to this hospital.The patient was a native of the Philippines who . . .
P115 EFFECT OF PURIFIED ALPHA 1-ANTITRYPSIN (AAT) ON EXPRESSION OF AAT IN NORMAL (PIMM) AND AAT DEFICIENT (PIZZ) PRIMARY HUMAN HEPATOCYTES
Authors: E.C.S. Ellis, H. Johansson, H. Zemack, C. Jorns, R. Gramignoli, S. Strom, G. Nowak, B.-G. Ericzon
Journal: Journal of Hepatology (2014)
Our Experiences in Preoperative Assesment of Esophageal Carcinoma with Endoscopic Ultrasound and Computed Tomography
Authors: D Ceranic, P Skok, B Veingerl
Journal: Endoscopy (2006)

Patients with advanced esophageal carcinoma have still poor prognosis independent of form of therapy. 5-year survival for patients with N1 stage is just 5–15% compared with those with N0 stage 40–60%. Patients with T4 stage have poor prognosis regardles of further therapy. Endoscopic ultrasonography is an excellent diagnostic tool in staging carcinoma for selecting proper therapeutical approach.
Single-CpG resolution mapping of 5-hydroxymethylcytosine by chemical labeling and exonuclease digestion identifies evolutionarily unconserved CpGs as TET targets
Authors: Aurélien A. Sérandour, Stéphane Avner, Elise A. Mahé, Thierry Madigou, Sylvain Guibert, Michaël Weber, Gilles Salbert
Journal: Genome biology (2016)

Conventional techniques for single-base resolution mapping of epigenetic modifications of DNA such as 5-hydroxymethylcytosine (5hmC) rely on the sequencing of bisulfite-modified DNA. Here we present an alternative approach called SCL-exo which combines selective chemical labeling (SCL) of 5hmC in genomic DNA with exonuclease (exo) digestion of the bead-trapped modified DNA molecules. Associated with a straightforward bioinformatic analysis, this new procedure provides an unbiased and fast method for mapping this epigenetic mark at high resolution. Implemented on mouse genomic DNA from in vitro-differentiated neural precursor cells, SCL-exo sheds light on an intrinsic lack of conservation of hydroxymethylated CpGs across vertebrates.
Incidence of pediatric melanoma in Texas: A report from the Texas Cancer Registry, 1995–2003
Authors: A. R. Spelman, M. F. Okcu, M. Bondy, A. Pappo
Journal: Journal of Clinical Oncology (2007)

8564 Background: Although melanoma is rare in the pediatric population, a sizable increase in the incidence of this disease has been previously reported in the pediatric population (J Clin Oncol 23:4735, 2005). In this study, we describe the incidence of pediatric melanoma in Texas in an effort to determine whether there has been a similar increase in Texas. Methods: Between 1995 and 2003, we identified 197 cases of melanoma (ICD codes 8720–8780) in children &lt; 20 years of age. Baseline characteristics were compared by chi-square analysis and age-adjusted incidence rates were calculated based on the US 2000 standard population. Results: Between 1995 and 2003, the incidence of pediatric melanoma in Texas increased by 57.2% (95% CI 42.4 to 72) per year of age. There was an 18.1% (95% CI 9.8 to 26.4) increased incidence per year for Texas in contrast to the 12% (95% CI 5.2 to 18.8) national increase (SEER). Fifty-three of 254 counties (20.9%) reported cases during this time period. Cases were diagnosed at a median age of 16 years (range 0–19). The majority of cases were non-Hispanic white (91.7%). Over half the cases (54.3%) were diagnosed at Stage I and the lesions were largely distributed between the extremities (39.1%), torso (28.9%) and head, face and neck (27.4%). Older individuals (10–19 years of age) were more likely to be female (p=0.024), non-Hispanic white (p&lt;0.001) and diagnosed at an earlier stage (p=0.023) than younger individuals (&lt;10 years of age). The incidence in older individuals was over 6 times that in the younger individuals (IRR=6.32, 95% CI 4.19–9.87) Conclusions: The incidence of pediatric melanoma in Texas has rapidly increased over that past 10 years. This increase emphasizes the need for public awareness, primary and secondary prevention campaigns and prospective studies to identify risk factors. No significant financial relationships to disclose.
Agranulocytosis Following Pyribenzamine
Authors: Alvin M. Cahan, Edward Meilman, Bernard M. Jacobson
Journal: New England Journal of Medicine (1949)

THE effectiveness of Pyribenzamine (tripelennamine hydrochloride) in many allergic states and its apparent freedom from toxicity have led to its widespread use with little fear of serious reaction. Thus far only 1 case of depression of the granulocytic series after Pyribenzamine therapy has been reported.1 The following case is believed to represent agranulocytosis resulting from the use of Pyribenzamine over a period of five and a half weeks.Case ReportA 39-year-old housewife entered the hospital complaining of sore tongue and mouth of 3 days' duration. The past history included migraine headache since the menarche, for which she had frequently . . .
AB1472-HPR Association between the age of the knee osteoarthritis manifestation and bone mineral density:
Authors: L. Alekseeva, E. Zaitseva, A. Smirnov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There are data demonstrated association between BMD and the risk of manifestation OA. Some researchers revealed association between high BMD score in hip and lumbar region and high risk of knee OA. <h3>Objectives</h3> To study of association between axis BMD and the age of the manifestation, clinical and instrumental features of OA. <h3>Methods</h3> 158 consecutive females aged 45 years and over with primary knee OA diagnosed according to the ACR criteria were included in the study. Bilateral knee radiographs was performed using posteroanterior position, DXA of lumbar spine and femoral neck was acquired on QDR-450w (Hologic). MRI and US of knee were performed. 74 patients with normal or increased spine BMD and 42 patients with osteoporosis (OP) were analyzed. <h3>Results</h3> OP had 30,8% patients, osteopenia - 14,7%, and normal or increased spine BMD had 54,4% patients. The duration of OA was comparable in all three groups. The manifestation of OA in the group with OP was in a older age (54,2±11,9 yr.) as compared with the group with osteopenia (47,5±10,4 yr.) and the group with normal BMD ((47±8,4 yr.) (P<sup>12</sup>=0,046, P<sup>13</sup>=0,005). The share of the person with early knee pain manifestation (before 45 yr.) among women with high or normal BMD was as twice more than among women with OP (67,6% vs 30% accordingly). At the age of over 45 yr. knee pain was in 32,4% in group with high or normal BMD and in 70% in group with OP. The odds ratio was 4,8 in group with early OA manifestation and high or normal lumbar BMD score. The OA stage was less among persons with combination of OA and OP. X-ray examination demonstrated more wide joint space and smaller osteophyte size in this persons. The results of the logistic regression analyses are presented in table. Overall percentage in logistic regression model = 93,0%. <h3>Conclusions</h3> Persons with high and normal lumbar BMD score have more early OA manifestation. <h3>Disclosure of Interest</h3> None Declared
Treatment of Recurrent Respiratory Papillomatosis with Human Leukocyte Interferon
Authors: Gerald B. Healy, Richard D. Gelber, Alicia L. Trowbridge, Kenneth M. Grundfast, Robert J. Ruben, Karen N. Price
Journal: New England Journal of Medicine (1988)

Recurrent respiratory papillomatosis is a relentless disease of viral origin in which squamous papillomas frequently obstruct the respiratory tract of children and young adults. No therapy has been proved to be curative for this process. Recent reports have suggested that interferon may cure or dramatically control airway papillomatosis. We evaluated the efficacy of human leukocyte interferon in the treatment of respiratory papillomatosis. One hundred twenty-three patients were randomly assigned to receive treatment with either surgery plus interferon or surgery alone. Interferon (2X106 IU per square meter of body-surface area) was given daily for one week, then three times per week for one year; treatment was followed by a year of observation, without the drug. Both study groups underwent serial endoscopy to remove papillomas and to document the efficacy of treatment during the two years of study. During the first six months, the growth rate of papillomas in the interferon group was significantly lower than in the control group (P = 0.0007). This difference diminished during the second six months and was no longer statistically significant (P = 0.68). Our data do not show that interferon is either curative or of substantial value as an adjunctive agent in the long-term management of recurrent respiratory papillomatosis. The initial benefit of interferon is not sustained. (N Engl J Med 1988;319:401–7.)
Impact of Patient Preparation on the Diagnostic Performance of 18F-FDG PET in Cardiac Sarcoidosis
Authors: Reuben Tang, Jeffrey Tzu-Yu Wang, Louis Wang, Ken Le, Yeqian Huang, Adam James Hickey, Louise Emmett
Journal: Clinical Nuclear Medicine (2015)

Purpose 18F-FDG PET/CT is a valuable diagnostic tool in the evaluation of cardiac sarcoidosis. Appropriate patient preparation is important because the diagnostic accuracy of this procedure depends on adequate suppression of physiologic glucose uptake. This systematic review and meta-analysis aims to assess the effect of different patient preparations on the diagnostic accuracy of 18F-FDG PET/CT in cardiac sarcoidosis. Patients and Methods We searched the PubMed/MEDLINE, Embase, and Cinicaltrials.gov databases. Sixteen studies (n = 559) were identified to be suitable for this systemic review. Studies were stratified according to fasting duration and means of physiologic suppression of 18F-FDG by cardiac tissue, which involves the use of heparin infusion or high-fat, low-carbohydrate diet before imaging. Study quality was assessed using the QUADAS-2 tool. Forest plots of sensitivity and specificity were calculated in Review Manager 5.3, and a random-effects hierarchical summary receiver operating characteristic model was created using MetaDiSc. Meta-regression was performed to investigate sources of heterogeneity. Results PET/CT had an overall Specificity of 0.75 (95% confidence interval [CI], 0.69–0.80) and specificity of 0.81 (95% CI, 0.76–0.85) for the diagnosis of cardiac sarcoidosis. This modest diagnostic accuracy was attributed to the inclusion of large single study in which a short fasting duration before scanning likely influenced its sensitivity. Its exclusion resulted in an overall sensitivity of 0.81 (95% CI, 0.76–0.86) and specificity of 0.82 (95% CI, 0.77–0.86). Meta-regression showed that the diagnostic odds ratio was significantly affected by fasting time and heparin administration before scanning (P = 0.01, 0.02) but not with high-fat, low-carbohydrate diet (P = 0.17). Conclusions 18F-FDG PET/CT plays an integral role in the diagnosis of cardiac sarcoidosis. Diagnostic accuracy is affected by fasting duration and means of cardiomyocyte glucose uptake suppression before scanning.
In Which Patients Can We Accurately Evaluate the Status of Axillary Lymph Node Metastases Using Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy?
Authors: H. Yagata, S. Nakamura, K. Tsugawa, H. Yamauchi, E. Nakano, A. Yoshida, M. Mori, Y. Kajiura, T. Onoda, Y. Takamoto, Y. Kojima, A. Kitano, R. In, N. Matsuda
Journal: Cancer Research (2009)

Abstract Background: Several studies have reported on the feasibility of sentinel lymph node (SLN) biopsy after neoadjuvant chemotherapy (NAC) in breast cancer patients. However, the accuracy has been variable depends on reports. We would like to determine in which patients we can accurately evaluate the status of axillary lymph node metastases using SLN biopsy after NAC in cytology-proved positive lymph node patients.Patients and Methods: Ninety-five cytology-proved node positive patients underwent SLN biopsy followed by axillary dissection between February 2007 and April 2009. All of those had clinical response in primary breast tumor detected by MRI after NAC.Results: SLN biopsy after NAC was successfully performed 81 out of 95 patients (85.3%). Among those 81 patients, lymph node metastases after NAC were identified by final pathology in 51 patients (63.0%). Eight of those 51 patients with lymph node metastases showed negative SLN biopsy. Therefore false negative rate was 15.7%. Patients who were diagnosed ER negative from the core needle specimen prior to NAC or had clinical CR by MRI did not showed any false negative by SLN biopsy. SLN were identified in 27 out of those 30 patients (90%). Final pathology after NAC revealed 7 patients with lymph node metastases and all of them had positive SLN. Twenty out of 27 (74.1%) patients revealed no evidence of metastases in both SLN and non-SLN.Discussion: After NAC, the false negative rate of SLN biopsies was high (15.7%) in cytology –proved lymph node-positive breast cancer patients. However, this study suggested that SLN biopsy after NAC may be performed accurately in patients who had ER negative tumor or CR by MRI, and that 20 out of 95 patients (21%) could possibly avoid axillary dissection after NAC. These results need to be confirmed by larger studies for the selected patients. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1036.
Abstract P1-07-04: Comparison of HER2 expression by immunohistochemistry (IHC) using automated imaging system and fluorescence in situ hybridization (FISH). A retrospective analysis of 2853 cases
Authors: R Collins, D Xiang, A Christie, M Leitch, D Euhus, R Rao, B Haley, V Sarode
Journal: Cancer Research (2012)

Abstract Background: Accurate assessment of HER2 status is critical for selecting patients who will benefit from trastuzumab therapy. There is still no consensus regarding the optimal method to assess HER2 status. Computerized image analysis has been shown to provide a more accurate and objective way for quantification of HER2 expression by IHC than manual evaluation. It has been suggested that the use of image analysis may help to resolve some of the discrepancies between IHC and FISH assay. We compared the results of HER2 expression by IHC using automated image analysis with fluorescent in situ hybridization (FISH) assay. Design: Testing for HER2 expression by IHC and FISH was performed on 2853 specimens at UT Southwestern Medical Center between the years 2002 to 2011. Quantification of IHC HER2 expression was done by image analysis and scored as positive (&amp;gt;2.0), borderline (1.5 to 2.0) and negative. (&amp;lt;1.5). The PathVysion kit was used for FISH assay to evaluate HER2 amplification. Ratios &amp;gt;2.0, 1.8 to 2.0 and &amp;lt;1.8 were defined positive, borderline and negative amplification respectively. Results: IHC compared to FISH Conclusion: Despite improvements in IHC testing, the FISH assay may be a better method for determining HER2 status. Factors such as tissue fixation, scoring methods and choice of antibodies may contribute to the lower specificity of IHC. In the amplified group, the gene amplification ratio correlated with protein expression, being highest in the IHC positive cases and lowest in those that were negative. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-07-04.
1995 NCI Appropriation Bills Under Way
Authors: D. A. Tisevich
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article 1995 NCI Appropriation Bills Under Way Get access Dorothy A. Tisevich Dorothy A. Tisevich Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 17, 7 September 1994, Page 1272, https://doi.org/10.1093/jnci/86.17.1272 Published: 07 September 1994
P2-17-02: Increased Progression Free and Overall Survival in Breast Cancer Patients with Menopausal Symptoms or Arthralgia/Myalgia during Adjuvant Treatment with Exemestane or Tamoxifen – Results of the German TEAM Trial.
Authors: P Hadji, DG Kieback, A Hasenburg, J Tams, M Ziller
Journal: Cancer Research (2011)

Abstract Background Previous studies have suggested a correlation between the occurrence of vasomotor or joint symptoms during tamoxifen or aromatase inhibitor treatment and improved clinical response. We assessed if there was any correlation between treatment-emergent adverse events during exemestane or tamoxifen treatment and clinical response. Methods: A retrospective analysis of the German cohort of the TEAM trial was performed to assess progression-free survival and overall survival in patients with and without menopausal symptoms or arthralgia/myalgia during adjuvant treatment with exemestane or tamoxifen. Results: A total of 1502 patients were included in this analysis; 739 patients received tamoxifen and 763 received exemestane. Patients reporting menopausal symptoms and patients reporting arthralgia/myalgia during tamoxifen or exemestane treatment had significantly longer overall survival and progression-free survival. The effect on overall survival was irrespective of treatment. Progression-free survival was significantly improved in exemestane-treated patients reporting menopausal symptoms or those reporting arthralgia/myalgia versus those not reporting these adverse events. There was no significant difference in progression-free survival between tamoxifen-treated patients reporting these symptoms versus those who did not. A combined analysis of patients reporting either menopausal symptoms or arthralgia/myalgia showed that overall survival and progressionfree survival was significantly improved in patients reporting one of these symptoms versus those not reporting either symptom. In this analysis, the effect on overall survival and progression-free survival was irrespective of treatment. Conclusions: Our results suggest that the occurrence of menopausal symptoms or arthralgia/myalgia during treatment with tamoxifen or exemestane is associated with significantly improved overall survival. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-17-02.
CORRELACION DIAGNOSTICA ECOENDOSCOPIA-CPRE EN EL DIAGNOSTICO DE LA COLEDOCOLITIASIS MEDIANTE ECOENDOSCOPIO SECTORIAL
Authors: A Pérez Millán, K De Jesus Geneaux, S Maestro Antolin, R Castillo Trujillo, F Igea Arisqueta
Journal: Endoscopy (2011)

Introducción: La ecoendoscopia se ha demostrado como un instrumento diagnostico eficaz en la exploración de la vía biliar. Determinar la existencia o no de litiasis en pacientes con cuadros biliares dudosos (Pancreatitis y cólicos biliares con bilirrubina <4) es de vital importancia para seleccionar pacientes que se pueden beneficiar de una CPRE y evitar riesgos innecesarios en el resto. No obstante la ecoendoscopia habitualmente utilizada en estos estudios es la endoscopia radial ya que en muchas unidades o bien no se dispone de ecoendoscopio sectorial o este se dedica solamente a punción dado que su radio de visión es menor. En nuestro caso por razones económico- organizativas no hemos dispuesto mas que de endoscopio sectorial hasta fecha reciente.